NicOx SA - Major Progress In 2013 In Building An International Ophthalmic Company

Published: Jan 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOPHIA ANTIPOLIS, France, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX) today provides a summary of its progress in 2013. In line with the strategy announced in 2012, Nicox is making rapid progress in building an international ophthalmic company with a range of ophthalmic diagnostics and eye care products marketed in the United States and in Europe. During this important evolution year, the Company launched Sjö, a novel diagnostic test, in the United States, acquired Eupharmed in Italy and saw its lead R&D asset latanoprostene bunod enter Phase 3 for glaucoma. The Company intends to continue expanding its portfolio through in-licensing, distribution and acquisition agreements.

Help employers find you! Check out all the jobs and post your resume.

Back to news